Tyra Biosciences press release (TYRA): Q1 GAAP EPS of -$0.64. – Cash, Cash Equivalents and Short-Term Investments.
As of March 31, 2026, TYRA had cash, cash equivalents and marketable securities of $383.5 million
The Company’s current cash, cash equivalents and marketable securities are expected to allow TYRA to execute